nfr-logonfr-logo
PROSJEKTBANKEN
Switch to English
Se statistikken
Se prosjektene

0 antall prosjekter

Dato fra ny til gammel

ERC-European Research Council (ERC)

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

The aim of this PoC project is to commercialize new therapy for acute lymphoblastic leukemia (ALL) developed in context of my ERC consolidator grant. T-cell receptors (TCRs) have in recent years emerged as promising therapeutic molecules in cell- and gene-therapy of cancer. I have completed the p...

Tildelt: kr 1,7 mill.

Prosjektperiode: 2023-2025

Sted: Oslo og 2 andre

CL1-Health

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Tildelt: kr 18,2 mill.

Prosjektperiode: 2023-2028

Sted: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.

Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, h...

Tildelt: kr 2,9 mill.

Prosjektperiode: 2023-2026

Sted: Oslo

CL1-Health

Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

Tildelt: kr 22,9 mill.

Prosjektperiode: 2022-2027

Sted: Telemark og 3 andre

CL1-Health

Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training.

Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training.

Tildelt: kr 34,8 mill.

Prosjektperiode: 2022-2026

Sted: Agder og 2 andre

H20-MSCA-Marie Sklodowska-Curie actions

SWIPT- MED: Simultaneous Wireless Information and Power Transfer for Medical Implants

SWIPT- MED: Simultaneous Wireless Information and Power Transfer for Medical Implants

Tildelt: kr 3,0 mill.

Prosjektperiode: 2021-2024

Sted: Oslo

H20-HEALTH-Health, demographic change and wellbeing

Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment.

More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current prac...

Tildelt: kr 64,0 mill.

Prosjektperiode: 2021-2026

Sted: Oslo og 2 andre

H20-MSCA-Marie Sklodowska-Curie actions

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Tildelt: kr 2,1 mill.

Prosjektperiode: 2019-2021

Sted: Oslo

H20-FET-Future and Emerging Technologies

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Tildelt: kr 18,8 mill.

Prosjektperiode: 2019-2024

Sted: Oslo og 2 andre

H20-ERC-European Research Council

Imaging Perfusion Restrictions from Extracellular Solid Stress

Imaging Perfusion Restrictions from Extracellular Solid Stress

Tildelt: kr 14,0 mill.

Prosjektperiode: 2018-2023

Sted: Oslo

H20-MSCA-Marie Sklodowska-Curie actions

High Performance Soft-tissue Navigation

Primary liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third most common cause of cancer mortality. A successful surgical resection of HCC requires complete removal of the tumour while sparing as much healthy tissue ...

Tildelt: kr 15,0 mill.

Prosjektperiode: 2016-2021

Sted: Trøndelag - Trööndelage og 2 andre

H20-FET-Future and Emerging Technologies

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours

Tildelt: kr 14,5 mill.

Prosjektperiode: 2016-2022

Sted: Oslo

H20-MSCA-Marie Sklodowska-Curie actions

Wireless In-Body Environment

Wireless In-Body Environment

Tildelt: kr 12,2 mill.

Prosjektperiode: 2016-2019

Sted: Oslo og 2 andre

1